Massive Bio Launches Game-Changing Chatbot Powered by ChatGPT for Easy Access to Oncology Trials at ASCO 2023

Massive Bio, a leading provider of personalized oncology solutions, has introduced its GPT4 AI chatbots, DrArturo AI and AskFiona AI, at ASCO 2023. These chatbots are powered by ChatGPT and are expected to redefine cancer care, setting new standards in patient and provider engagement and global oncological research. Incorporating these chatbots into its existing SYNERGY-AI Clinical Trial Matching Solution, the company aims to further promote patient empowerment and reduce the reliance on hospital-specific healthcare. With AskFiona AI, cancer patients will have access to clearer information on clinical trial purposes and protocols, along with assessments of patient eligibility, while DrArturo AI offers personalized information about specific clinical trials, including treatment details and insurance acceptance, to physicians and site investigators. Massive Bio has more than three dozen clients, including pharmaceutical companies, contract research organizations, and hospital networks. The company is committed to empowering cancer patients to discover their optimal treatment options using AI and facilitating data-driven cancer treatment.